A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109

por Mina, Lida A., Yu, Menggang, Johnson, Cynthia, Burkhardt, Cyndi, Miller, Kathy D., Zon, Robin
Publicado 2013